GLOW 2 BlendExplore study findings
What the 2026 MOTS c Appraisal Means for Claims About GLOW 2
2 numbered sourcesSource years 2026
A peptide is a short chain of amino acids linked by peptide bonds. A research blend can contain several such materials, each with a different evidence base. The GLOW 2 formulation described in the catalog names the mitochondrial peptide MOTS-c together with GHK-Cu and BPC-157. The exact preparation has not been confirmed. Federal documents that discuss MOTS-c provide useful context for assessing what is known about that ingredient. They do not supply a clinical evaluation of GLOW 2. [1, 2]
In 2026, FDA staff prepared a briefing on MOTS-c-related bulk drug substances for its Pharmacy Compounding Advisory Committee. The document identifies the materials considered and discusses the available information for the proposed uses. This type of review can draw attention to limitations in the human record. It is not a study in which a new group of people received a GLOW 2 preparation and was followed for benefit or harm. [1]
Later that year, HHS issued an interim enforcement discretion policy under specified conditions. The policy names certain defined peptide substances and limits its scope to a product containing a single listed active ingredient. A catalog name for three materials does not meet the description of a single active ingredient. The policy does not amount to FDA approval of either the blend or the named ingredients for any claimed outcome. [2]
A helpful way to read a claim about GLOW 2 is to ask what evidence it points to. If it points to an official review, check which substance the review addresses. If it points to an experiment, check whether the actual mixture was tested. That distinction protects against turning evidence about an individual peptide into a conclusion about the whole formulation.
Sources
Original works cited in this article. Links open the external record in a new tab.
